2 weeks Ago By ABMN Staff
HBK Sorce Advisory LLC decreased its holdings in iShares Biotechnology ETF ( NASDAQ:IBB – Free Report ) by 18.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,283 shares of the financial services provider’s stock after selling 529 shares during the quarter.
HBK Sorce Advisory LLC’s holdings in iShares Biotechnology ETF were worth $313,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Blue Fin Capital Inc.
grew its holdings in shares of iShares Biotechnology ETF by 0.7% in the second quarter. Blue Fin Capital Inc.
now owns 10,516 shares of the financial services provider’s stock worth $1,443,000 after acquiring an additional 74 shares during the period. Crewe Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 42.9% during the 4th quarter.
Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock valued at $35,000 after purchasing an additional 78 shares during the period. Main Street Financial Solutions LLC increased its position in shares of iShares Biotechnology ETF by 1.0% during the 2nd quarter.
Main Street Financial Solutions LLC now owns 8,002 shares of the financial services provider’s stock valued at $1,098,000 after purchasing an additional 82 shares during the last quarter. Perkins Coie Trust Co lifted its stake in shares of iShares Biotechnology ETF by 0.3% in the 2nd quarter.
Perkins Coie Trust Co now owns 25,184 shares of the financial services provider’s stock worth $3,457,000 after purchasing an additional 83 shares during the period. Finally, HCR Wealth Advisors boosted its holdings in shares of iShares Biotechnology ETF by 0.6% in the second quarter.
HCR Wealth Advisors now owns 13,453 shares of the financial services provider’s stock worth $1,847,000 after buying an additional 83 shares during the last quarter. Institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance Shares of NASDAQ IBB opened at $147.81 on Monday. iShares Biotechnology ETF has a 12-month low of $111.
83 and a 12-month high of $150.17. The firm has a 50 day moving average of $145.
10 and a 200 day moving average of $138.27. iShares Biotechnology ETF Profile iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF).
The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. See Also Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.
com's FREE daily email newsletter ..
